Literature DB >> 24986227

Psychosocial factors in adjuvant hormone therapy for breast cancer: an emerging context for adherence research.

Julia R Van Liew1, Alan J Christensen, Janet S de Moor.   

Abstract

PURPOSE: For patients with hormone receptor positive breast cancer, survivorship entails prolonged self-management of adjuvant treatment in the form of daily hormone therapy. Although sustained daily adherence across the 5-year course of therapy is associated with improved recurrence-free survival outcomes, adherence is suboptimal and many women discontinue hormone therapy prematurely. Factors associated with breast cancer survivors' nonadherence and nonpersistence are not comprehensively understood. Furthermore, psychosocial variables have only received limited research attention, despite their documented relationships with adherence in other chronic illness populations.
METHODS: A systematic literature review identified 14 studies that analyzed relationships between psychosocial factors and breast cancer survivors' adherence and/or persistence with adjuvant hormone therapy.
RESULTS: Although identified relationships were complex and at times inconsistent, salient conclusions emerged. Interpersonal factors, in the form of positive social support and patient-centered interactions with medical providers, as well as intrapersonal factors, such as anxiety and beliefs about the relative benefits of medication use, were reliably associated with better adherence and persistence. Depression did not demonstrate the negative impact on adherence that has been observed in other medical populations. No relationships between quality of life and adherence were identified.
CONCLUSIONS: Adjuvant hormone therapy appears to be a unique context for medication adherence, which warrants further attention and more rigorous analysis in future research. IMPLICATIONS FOR CANCER SURVIVORS: Individual patients' psychosocial characteristics and health care preferences should be considered when striving to optimize medication adherence.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24986227     DOI: 10.1007/s11764-014-0374-2

Source DB:  PubMed          Journal:  J Cancer Surviv        ISSN: 1932-2259            Impact factor:   4.442


  38 in total

1.  A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: summarizing the data for clinicians.

Authors:  Laetitia Huiart; Cyril Ferdynus; Roch Giorgi
Journal:  Breast Cancer Res Treat       Date:  2013-02-12       Impact factor: 4.872

2.  Patient and physician beliefs about control over health: association of symmetrical beliefs with medication regimen adherence.

Authors:  Alan J Christensen; M Bryant Howren; Stephen L Hillis; Peter Kaboli; Barry L Carter; Jamie A Cvengros; Kenneth A Wallston; Gary E Rosenthal
Journal:  J Gen Intern Med       Date:  2010-02-20       Impact factor: 5.128

Review 3.  Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy.

Authors:  David Cella; Lesley J Fallowfield
Journal:  Breast Cancer Res Treat       Date:  2007-09-18       Impact factor: 4.872

4.  Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis.

Authors:  P Hadji; V Ziller; J Kyvernitakis; M Bauer; G Haas; N Schmidt; K Kostev
Journal:  Breast Cancer Res Treat       Date:  2013-01-20       Impact factor: 4.872

5.  Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication.

Authors:  Yihang Liu; Jennifer L Malin; Allison L Diamant; Amardeep Thind; Rose C Maly
Journal:  Breast Cancer Res Treat       Date:  2012-12-23       Impact factor: 4.872

6.  Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use.

Authors:  Katherine L Kahn; Eric C Schneider; Jennifer L Malin; John L Adams; Arnold M Epstein
Journal:  Med Care       Date:  2007-05       Impact factor: 2.983

7.  Associations between adjuvant endocrine therapy and onset of physical and emotional concerns among breast cancer survivors.

Authors:  G J van Londen; E B Beckjord; M A Dew; K L Cooper; N E Davidson; D H Bovbjerg; H S Donovan; R C Thurston; J Q Morse; S Nutt; R Rechis
Journal:  Support Care Cancer       Date:  2013-11-24       Impact factor: 3.603

8.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.

Authors:  C Davies; J Godwin; R Gray; M Clarke; D Cutter; S Darby; P McGale; H C Pan; C Taylor; Y C Wang; M Dowsett; J Ingle; R Peto
Journal:  Lancet       Date:  2011-07-28       Impact factor: 79.321

9.  Physicians' influence on breast cancer patient compliance.

Authors:  Karel Kostev; Lilia Waehlert; Achim Jockwig; Barbara Jockwig; Peyman Hadji
Journal:  Ger Med Sci       Date:  2014-01-20

10.  Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer.

Authors:  C McCowan; J Shearer; P T Donnan; J A Dewar; M Crilly; A M Thompson; T P Fahey
Journal:  Br J Cancer       Date:  2008-11-04       Impact factor: 7.640

View more
  25 in total

1.  It's not an easy fix: Adherence to adjuvant endocrine therapy after breast cancer.

Authors:  Leah K Lambert; Lynda G Balneaves; A Fuchsia Howard
Journal:  Can Oncol Nurs J       Date:  2021-05-01

2. 

Authors:  Leah K Lambert; Lynda G Balneaves; A Fuchsia Howard
Journal:  Can Oncol Nurs J       Date:  2021-05-01

3.  Everolimus induced mood changes in breast cancer patients: a case-control study.

Authors:  Olivier Mir; Alexandre Salvador; Sarah Dauchy; Stanislas Ropert; Cédric Lemogne; Raphaël Gaillard
Journal:  Invest New Drugs       Date:  2017-12-18       Impact factor: 3.850

4.  Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the Breast Cancer Quality of Care Study (BQUAL).

Authors:  Dawn L Hershman; Lawrence H Kushi; Grace Clarke Hillyer; Ellie Coromilas; Donna Buono; Lois Lamerato; Dana H Bovbjerg; Jeanne S Mandelblatt; Wei-Yann Tsai; Xiaobo Zhong; Judith S Jacobson; Jason D Wright; Alfred I Neugut
Journal:  Breast Cancer Res Treat       Date:  2016-04-16       Impact factor: 4.872

5.  Investigating Associations Between Health-Related Quality of Life and Endocrine Therapy Underuse in Women With Early-Stage Breast Cancer.

Authors:  Laura C Pinheiro; Stephanie B Wheeler; Katherine E Reeder-Hayes; Cleo A Samuel; Andrew F Olshan; Bryce B Reeve
Journal:  J Oncol Pract       Date:  2017-03-14       Impact factor: 3.840

6.  Perceived barriers to treatment predict adherence to aromatase inhibitors among breast cancer survivors.

Authors:  Moriah J Brier; Dianne L Chambless; Robert Gross; Jinbo Chen; Jun J Mao
Journal:  Cancer       Date:  2016-08-29       Impact factor: 6.860

7.  Symptoms and QOL as Predictors of Chemoprevention Adherence in NRG Oncology/NSABP Trial P-1.

Authors:  Stephanie R Land; Farzana L Walcott; Qing Liu; D Lawrence Wickerham; Joseph P Costantino; Patricia A Ganz
Journal:  J Natl Cancer Inst       Date:  2015-11-27       Impact factor: 13.506

8.  Barriers and facilitators to endocrine therapy adherence among underserved hormone-receptor-positive breast cancer survivors: a qualitative study.

Authors:  Kristen J Wells; Tonya M Pan; Coralia Vázquez-Otero; Danielle Ung; Amy E Ustjanauskas; Dariana Muñoz; Christine Laronga; Richard G Roetzheim; Marissa Goldenstein; Claudia Carrizosa; Sumayah Nuhaily; Kenneth Johnson; Marilyn Norton; Elizabeth Sims; Gwendolyn P Quinn
Journal:  Support Care Cancer       Date:  2016-05-05       Impact factor: 3.603

9.  Adjuvant endocrine therapy for breast cancer patients: impact of a health system outreach program to improve adherence.

Authors:  Catherine Lee; Devon K Check; Leslie Manace Brenman; Lawrence H Kushi; Mara M Epstein; Christine Neslund-Dudas; Pamala A Pawloski; Ninah Achacoso; Cecile Laurent; Louis Fehrenbacher; Laurel A Habel
Journal:  Breast Cancer Res Treat       Date:  2020-01-23       Impact factor: 4.872

10.  A systematic review of interventions to improve adherence to endocrine therapy.

Authors:  Sue P Heiney; Pearman D Parker; Tisha M Felder; Swann Arp Adams; Omonefe O Omofuma; Jennifer M Hulett
Journal:  Breast Cancer Res Treat       Date:  2018-11-01       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.